Less than two months after Nevada enacted a controversial law requiring more transparency from drug makers over their pricing of diabetes medicines, the pharmaceutical industry is pushing back.
In a lawsuit filed last Friday, two large industry trade groups claim the law is an “unprecedented and unconstitutional” action that interferes with well-established patent law by robbing drug makers of their right to protect trade secrets. Consequently, the trade groups also argue the law impedes the ability to successfully to do business in other states by tying penalties to wholesale, or list, prices.
About the Author Reprints
